why choose us

First received: August 8, 2022

Clinical Trial: Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma

Study Status: Active, not recruiting

Recruit Status: Active, not recruiting

Condition: Esophageal Squamous Cell Carcinoma

Study Type: Interventional


Official Title: Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma: A Multi-Centre, Open-Label, Randomized, Controlled, Clinical Trial (HCHTOG2203)

Brief Summary: No adjuvant treatment has been established for patients who remain at high risk for recurrence after neoadjuvant chemotherapy plus surgery and incidental pathologic lymph node metastasis following initial surgery for esophageal squamous cell carcinoma (ESCC).Controversy still exists regarding the role of adjuvant immunotherapy for ESCC patients who do not achieve pCR after neoadjuvant chemotherapy plus surgery and clinical T1-2 N0 patients with incidental pathologic lymph node metastasis following initial surgery.…

Read more